Search

As FDA is recognized as an authoritative body by Proposition 65, we believe that OEHHA should await the outcome of FDA's review rather than bringing BP-3 to the DARTIC for review.

These comments are submitted as supporting evidence for the safety of the spray dosage from of sunscreens and is referenced in the comments filed to this docket by PCPC and CHPA.

Enclosed herein are comments on "Guidance for Industry; Nonprescription Sunscreen Drug Products - Content and Format of Data Submissions to Support a GRASE determination Under the Sunscreen Innovation Act."

Comments regarding guidance for industry pertaining to sunscreen ingredients requesting inclusion into the OTC sunscreen monograph.

These comments address titanium dioxide nanoparticles, which serve an important function in numerous consumer products, including sunscreens.

Personal Care Products Council and CHPA comments in response to FDA rule regarding labeling and effectiveness requirements for certain OTC sunscreen products.

CHPA applauds the approach for creating a public forum to collect current research and comments to advance the science of engineered nanomaterials.

Because of their well-established role in protecting public health, the significant benefits provided by sunscreens need to be appropriately weighed against any potential risks. We support FDA’s commitment to ensuring that sunscreens are safe and effective for their intended use.

The PCPC and CHPA are pleased to provide these comments in response to FDA's proposed amendment to the final monograph for OTC sunscreen drug products for human use.